Floatz Rating
B63/100
Confidence
Indicative
Sponsor
GV20 Therapeutics
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07623642CT.gov A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors. | — | Not Yet Recruiting | — | — | — |
NCT06704724CT.gov A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. | — | Terminated | — | — | — |
NCT06447662CT.gov A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | — | Recruiting | — | — | — |
NCT06400472CT.gov A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05333809CT.gov Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer | — | Unknown | — | — | — |
NCT05239741CT.gov Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) | — | Active Not Recruiting | — | — | — |
NCT05091346CT.gov A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | — | Completed | — | — | — |
NCT04956640CT.gov Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | — | Active Not Recruiting | — | — | — |
NCT04776148CT.gov Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) | — | Completed | — | — | — |
NCT03948763CT.gov A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | — | Terminated | — | — | — |
Show 4 more trialsShow fewer
NCT03519412CT.gov Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status | — | Completed | — | — | — |
NCT03631407CT.gov Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) | — | Completed | — | — | — |
NCT03485209CT.gov Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02952989CT.gov A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | GV20 Therapeutics | P3 | B · 63 |
| Oxaliplatin | Peking University Cancer Hospital & Institute | P4 | BBB |
| Fluorouracilum | Rutgers, The State University of New Jersey | P4 | BBB |
| Irinotecan | Shanghai Zhongshan Hospital | P4 | BBB |
| Ferric Carboxymaltose [Ferinject] | Nottingham University Hospitals NHS Trust | P4 | BBB |
| Capecitabine | Rutgers, The State University of New Jersey | P4 | BB |
| Regorafenib | Sergey Orlov, MD | P4 | BB |
| Nivolumab | Bristol-Myers Squibb | P3 | BB |
| Iron(Ii) Sulphate (1:1), Heptahydrate | Nottingham University Hospitals NHS Trust | P4 | BB |
+41 more in the Colorectal Neoplasm cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Colorectal Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-colorectal-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →